Investigation of the possible neuroprotective effect of SGLT2 inhibitors in rotenone lesioned rats / (Record no. 178743)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06918namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260310111316.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260225s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.Ph.D.2025.Ah.I |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Ahmed Mohamed Abdelaziz Mohamed, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Investigation of the possible neuroprotective effect of SGLT2 inhibitors in rotenone lesioned rats / |
| Statement of responsibility, etc. | by Ahmed Mohamed Abdelaziz Mohamed ; Supervision Dr. Rehab Mahmoud Mohammed El-Sayed, Dr. Nora Osama Abdel Rasheed, Dr. Hala Ahmed Fahmy Zaki, Dr. Hesham Aly Salem. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | التحقق من امكانية التأثير الواقي للأعصاب لمثبطات SGLT2 في الجرذان المتأذية بالروتينون |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 113 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 94-113. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Despite the profound comprehension of Parkinson's disease (PD) and <br/>levodopa-induced dyskinesia (LID) pathogenesis, current therapies are <br/>insufficient to effectively manage the progressive nature of PD or halt LID. <br/>Growing hypotheses suggested the NOD-like receptor 3 (NLRP3) inflammasome <br/>and orphan nuclear receptor-related 1 (Nurr1)/glycogen synthase kinase-3β <br/>(GSK-3β) and peroxisome proliferator-activated receptor γ (PPARγ) coactivator-<br/>1α (PGC-1α)/sirtuin 3 (SIRT3) pathways as potential avenues for halting <br/>neuroinflammation and oxidative stress in PD. <br/>Aims: This study investigated for the first time the neuroprotective effect of <br/>canagliflozin against PD and LID in rotenone-intoxicated rats, emphasizing the <br/>crosstalk among the NLRP3/caspase-1 cascade, PGC-1α/SIRT3 pathway, <br/>mammalian target of rapamycin (mTOR)/beclin-1, and Nurr1/β-catenin/GSK-3β <br/>pathways as possible treatment strategies in PD and LID. Also, correlating <br/>NLRP3 expression with all evaluated parameters. <br/>Main methods: The PD rat model was induced via eleven rotenone (1.5 mg/kg) <br/>subcutaneous injections day after day. Canagliflozin (20 mg/kg) and/or L-<br/>dopa/carbidopa (100/25 mg/kg) were orally administered daily from the <br/>beginning till the end of the experiment. <br/>Key findings: Canagliflozin significantly improved neurobehavioral and <br/>histological assessments, whereas dyskinesia scores declined. The improvement <br/><br/><br/> <br/><br/> <br/><br/> <br/><br/>was confirmed immunohistochemically through tyrosine hydroxylase and β-<br/>catenin upregulation in contrast to NLRP3 and caspase-1 downregulation in <br/>substantia nigra pars compacta. In addition, canagliflozin induced a prominent <br/>elevation in dopamine, Nurr1, PGC-1α, SIRT3, and beclin-1, whereas mTOR and <br/>GSK-3β expressions were downregulated. <br/>Significance: Current results revealed the aspiring canagliflozin neuroprotective <br/>properties against PD and LID in rotenone-lesioned rats via the assumed anti-<br/>inflammatory activity and implication of NLRP3/caspase-1, Nurr1/GSK-3β/β-<br/>catenin, PGC-1α/SIRT3, and beclin-1/mTOR pathways. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | لا توجد الية فعالة للحد من تدهور مرض الشلل الرعاش وحدوث خلل الحركة الناتج عن عقار ليفودوبا المستخدم في العلاج. أشارت الدراسات السابقة إلى أن مستقبلات NLRP3 ومساري/ Nurr 1 GSK-<br/> 3βوSIRT3/ PGC-1α ويعملون على الحد من الالتهاب العصبي والإجهاد التأكسدي في مرض الشلل الرعاش <br/>الأهداف: بحثت هذه الدراسة لأول مرة في التأثير العصبي الواقي للكاناجليفلوزين ضد مرض الشلل الرعاش واضطراب الحركة الناتج عن عقار ليفودوبا في الجرذان. حرصت الدراسة على تسليط الضوء على التداخل بين المسارات الاتية NLRP3/caspase-1;، وPGC-1α/SIRT3، وmTOR/beclin-1، وNurr1/β-catenin/GSK-3β كاستراتيجيات علاجية محتملة في مرض الشلل الرعاش واضطراب الحركة الناتج عن ليفودوبا مع ربط تعبير NLRP3 بجميع المؤشرات التي تم تقييمها. <br/>الطرق الرئيسية: تم حقن الجرذان 11 حقنة تحت الجلد من مادة الروتينون (1.5 ملغ/كغ) يومًا بعد يوم. تم إعطاء كاناجليفلوزين (20 ملغ/كغ) و/أو (ليفودوبا/كاربيدوبا) (100/25 ملغ/كغ) عن طريق الفم يوميًا من البداية حتى نهاية التجربة. <br/>النتائج الرئيسية: حسّن عقار كاناجليفلوزين بشكل كبير التقييمات العصبية السلوكية والنسيجية، في حين انخفضت مؤشرات الخلل الحركي. تم تأكيد التحسن من خلال زيادة TH وβ-catenin مقارنةً بـ انخفاض NLRP3 وcaspase-1 في SNpc. أدى الكاناجليفلوزين إلى ارتفاع ملحوظ في مستويات الدوبامين، Nurr1، PGC-1α، SIRT3، وbeclin-1، في حين تم تقليص تعبيرات mTOR و. GSK-3β<br/>الأهمية: كشفت نتائجنا عن الخصائص العصبية الواقية الواعدة للكاناجليفلوزين ضد مرض الشلل الرعاش والخلل الحركي الناتج عن عقار ليفودوبا في الفئران المتأذية بالروتينون بواسطة ضبط المسارات الاتية NLRP3/caspase-1، Nurr1/GSK-3β/β-catenin، PGC-1α/SIRT3، وbeclin-1/mTOR مما يحد من الالتهاب العصبي المفرط المصاحب لمرض الشلل الرعاش. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmacology and Toxicology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الأدوية والسموم |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Parkinson’s disease |
| -- | Dyskinesia |
| -- | Rotenone |
| -- | Canagliflozin |
| -- | NLRP3/Nurr1/GSK-3β/β-catenin |
| -- | PGC-1α/SIRT3/beclin-1 |
| -- | مرض الشلل الرعاش |
| -- | خلل الحركة |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rehab Mahmoud Mohammed El-Sayed |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nora Osama Abdel Rasheed |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hala Ahmed Fahmy Zaki |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hesham Aly Salem |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Rehab Mahmoud Mohammed El-Sayed |
| -- | Nora Osama Abdel Rasheed |
| -- | Hala Ahmed Fahmy Zaki |
| -- | Hesham Aly Salem |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology and Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 25.02.2026 | 93459 | Cai01.08.09.Ph.D.2025.Ah.I | 01010110093459000 | 25.02.2026 | 25.02.2026 | Thesis |